Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL (Ph+ ALL-2026)
A Prospective, Umbrella, Phase 2 Study of Immunotargeted Agents Combined With Low-Dose Chemotherapy in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia
This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 22 adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (ALL).
As an umbrella trial, all patients share the same target disease (newly diagnosed Ph+ B-ALL) and receive a uniform induction backbone consisting of multi-targeted immunotherapy, targeted therapy, and reduced-intensity chemotherapy. After induction, patients are stratified and assigned to two distinct consolidation pathways based on clinical condition, performance status, resource availability, and patient preference:
Pathway A: Consolidation with CD19-directed CAR-T cell therapy to achieve deep molecular remission; Pathway B: Consolidation with sequential immunochemotherapy to maximize minimal residual disease (MRD) clearance.
A backup chemotherapy backbone is provided for patients ineligible for antibody therapy. All patients, regardless of consolidation pathway, proceed to a unified long-term maintenance regimen. The primary endpoint is the complete molecular remission (CMR) rate after one cycle of induction therapy. MRD is monitored longitudinally by flow cytometry, quantitative PCR, and immune repertoire sequencing. Safety is evaluated per NCI CTCAE version 5.0.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Ying Wang, MD, PhD
- Telefonnummer: +86 22-23608095
- E-Mail: wangying1@ihcams.ac.cn
Studienorte
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 301600
- Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology)
-
Kontakt:
- Runxia Gu
- Telefonnummer: +86-22-23608095
- E-Mail: gurunxia@ihcams.ac.cn
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥ 18 years
- Newly diagnosed, previously untreated Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) confirmed by cytogenetics and/or molecular testing
- Leukemic blasts expressing CD22
- Adequate organ function (renal, hepatic, cardiac)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Life expectancy ≥ 3 months
- Written informed consent obtained prior to any study-related procedures
Exclusion Criteria:
- Prior systemic anti-leukemic therapy, including chemotherapy, targeted therapy, or immunotherapy
- History of chronic myeloid leukemia (CML) or other hematologic malignancies
- Central nervous system (CNS) leukemia or extramedullary disease at diagnosis
- Uncontrolled active infection or severe comorbidities
- HIV positivity or known hepatitis B/C infection with active viral replication
- Pregnant or breastfeeding
- Inability to comply with study procedures or follow-up requirements
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Immunotargeted Therapy + Low-Dose Chemotherapy Arm
All patients receive a uniform induction therapy backbone combining targeted therapy, immunotherapy, and reduced-intensity chemotherapy. After induction, patients are stratified into two consolidation pathways based on clinical status: 1) CD19 CAR-T cell therapy; 2) sequential immunochemotherapy. All patients proceed to a unified long-term maintenance regimen. |
Third-generation tyrosine kinase inhibitor (TKI) targeting BCR::ABL1, administered orally daily as part of induction, consolidation, and maintenance therapy. BCL-2 inhibitor administered orally daily during induction and consolidation cycles to enhance leukemic cell apoptosis. Anti-CD22 antibody-drug conjugate (ADC) administered intravenously during induction and consolidation therapy. CD19/CD3 bispecific T-cell engager (BiTE) administered as continuous intravenous infusion during consolidation therapy. Autologous CD19 CAR-T cell therapy administered as a single intravenous infusion as optional consolidation therapy for eligible patients. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Complete Molecular Remission (CMR) Rate After 1 Cycle of Induction Therapy
Zeitfenster: At the end of Cycle 1 (each cycle is 28 days, approximately 4 weeks from enrollment)
|
The proportion of patients achieving complete molecular remission (CMR), defined as undetectable BCR::ABL1 transcript by quantitative PCR (BCR::ABL1/ABL1 ratio < 0.001%), after 1 cycle of induction therapy. |
At the end of Cycle 1 (each cycle is 28 days, approximately 4 weeks from enrollment)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
3-Month Complete Remission (CR)
Zeitfenster: 3 months after study enrollment
|
3 months after study enrollment
|
|
|
3-Month MRD Negativity Rates
Zeitfenster: 3 months after study enrollment
|
3 months after study enrollment
|
|
|
2-Year Overall Survival (OS)
Zeitfenster: 2 years after the last patient enrollment
|
OS is defined as the time from study enrollment to death from any cause. |
2 years after the last patient enrollment
|
|
2-Year Disease-Free Survival (DFS)
Zeitfenster: 2 years after the last patient enrollment
|
DFS is defined as the time from study enrollment to disease relapse or death from any cause. |
2 years after the last patient enrollment
|
|
2-Year Event-Free Survival (EFS)
Zeitfenster: 2 years after the last patient enrollment
|
EFS is defined as the time from study enrollment to first occurrence of predefined adverse events, disease progression or death. |
2 years after the last patient enrollment
|
|
Incidence of Treatment-Related Adverse Events (TRAEs)
Zeitfenster: From study enrollment to 60 days after the last treatment
|
Number and severity of adverse events graded according to NCI CTCAE version 5.0. |
From study enrollment to 60 days after the last treatment
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IIT2026061
- IIT2026061-EC-1 (Andere Kennung: Ethics Committee of Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .